Human Genome Epidemiology Literature Finder
Records 1 - 30 (of 208 Records) |
Query Trace: Breast Neoplasms and CYP2D6[original query] |
---|
Chinese breast cancer patients with CYP2D6*10 mutant genotypes have a better prognosis with toremifene than with tamoxifen. Asia-Pacific journal of clinical oncology 2021 7 18 (2): e148-e153. Wang Hongyue, Ma Xinchi, Zhang Bin, Zhang Yaotian, Han Ning, Wei Linlin, Sun Chaonan, Sun Shichen, Zeng Xue, Guo Hong, Li Yubing, Zhang Yanyu, Zhao Jiaming, Qin Zilan, Liu Zhuang, Zhang |
A Population Pharmacokinetic Meta-Analysis of Veliparib, a PARP Inhibitor, Across Phase 1/2/3 Trials in Cancer Patients. Journal of clinical pharmacology 2021 Apr . Stodtmann Sven, Nuthalapati Silpa, Eckert Doerthe, Kasichayanula Sreeneeranj, Joshi Rujuta, Bach Bruce A, Mensing Sven, Menon Rajeev, Xiong H |
Clinical CYP2D6 Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a Controversy. Cancers 2021 3 13 (4): . Mulder Tessa A M, de With Mirjam, Del Re Marzia, Danesi Romano, Mathijssen Ron H J, van Schaik Ron H |
Biochip-based approach for comprehensive pharmacogenetic testing. Drug metabolism and personalized therapy 2020 Dec . Ikonnikova Anna Yu, Filippova Marina A, Surzhikov Sergey A, Pozhitnova Victoria O, Kazakov Ruslan E, Lisitsa Tatiana S, Belkov Sergey A, Nasedkina Tatiana |
Association of CYP2D6 genotype and tamoxifen metabolites with breast cancer recurrence in a low-dose trial. NPJ breast cancer 2021 Mar 7 (1): 34. DeCensi Andrea, Johansson Harriet, Helland Thomas, Puntoni Matteo, Macis Debora, Aristarco Valentina, Caviglia Silvia, Webber Tania Buttiron, Briata Irene Maria, D'Amico Mauro, Serrano Davide, Guerrieri-Gonzaga Aliana, Bifulco Ersilia, Hustad Steinar, Søiland Håvard, Boni Luca, Bonanni Bernardo, Mellgren Gunn |
Evaluating the Risk of Breast Cancer Recurrence and Metastasis After Adjuvant Tamoxifen Therapy by Integrating Polymorphisms in Cytochrome P450 Genes and Clinicopathological Characteristics. Frontiers in oncology 2021 12 11 738222. Pang Hui, Zhang Guoqiang, Yan Na, Lang Jidong, Liang Yuebin, Xu Xinyuan, Cui Yaowen, Wu Xueya, Li Xianjun, Shan Ming, Wang Xiaoqin, Meng Xiangzhi, Liu Jiaxiang, Tian Geng, Cai Li, Yuan Dawei, Wang X |
Comparison of adverse drug reactions between tamoxifen and toremifene in breast cancer patients with different CYP2D6 genotypes: A propensity-score matched cohort study. International journal of cancer 2021 12 150 (10): 1664-1676. Zhou Weihang, Jiang Yiwei, Xu Yaqian, Wang Yaohui, Ma Xiaowei, Zhou Liheng, Lin Yanping, Wang Yan, Wu Ziping, Li Min, Yin Wenjin, Lu Jinso |
Preliminary Pharmacogenomic-Based Predictive Models of Tamoxifen Response in Hormone-dependent Chilean Breast Cancer Patients. Frontiers in pharmacology 2021 12 12 661443. Miranda Carla, Galleguillos Macarena, Torres Roberto, Tardón Karla, Cáceres Dante D, Lee Kuen, Redal María A, Varela Nelson M, Quiñones Luis |
Genetic polymorphisms on the effectiveness or safety of breast cancer treatment: Clinical relevance and future perspectives. Mutation research. Reviews in mutation research 2021 12 788 108391. Cura Yasmin, Pérez Ramírez Cristina, Sánchez Martín Almudena, Martínez Martínez Fernando, Calleja Hernández Miguel Ángel, Ramírez Tortosa María Del Carmen, Jiménez Morales Alber |
Impact of cytochrome P450 2D6 polymorphisms on decision-making and clinical outcomes in adjuvant hormonal therapy for breast cancer. World journal of clinical oncology 2022 9 13 (8): 712-724. Tan Ern-Yu, Bharwani Lavina, Chia Yee-Hong, Soong Richie C T, Lee Sherylyn S Y, Chen Juliana J C, Chan Patrick M |
(Z)-Endoxifen and Early Recurrence of Breast Cancer: An Explorative Analysis in a Prospective Brazilian Study. Journal of personalized medicine 2022 4 12 (4): . Almeida Thais, Schroth Werner, Nardin Jeanine, Mürdter Thomas E, Winter Stefan, Picolotto Solane, Hoppe Reiner, Kogin Jenifer, Gaio Elisa, Dasenbrock Angela, Skrsypcsak Raquel Cristina, de Noronha Lucia, Schwab Matthias, Brauch Hiltrud, Casali-da-Rocha José Claud |
Design and implementation of a novel pharmacogenetic assay for the identification of the CYP2D6*10 genetic variant. BMC research notes 2022 3 15 (1): 104. Ranadeva Nadeeka Dimuthu Kumari, Sirisena Nirmala Dushyanthi, Wetthasinghe Tithila Kalum, Noordeen Nafeesa, Dissanayake Vajira Harshadeva Weerabadda |
Value of therapeutic drug monitoring of endoxifen in Egyptian premenopausal patients with breast cancer given tamoxifen adjuvant therapy: A pilot study. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2022 12 10781552221146531. El Desoky Ehab S, Taha Amira F, Mousa Heba Salah, Ibrahim Abeer, Saleh Medhat A, Abdelrady Mohamed A, Hareedy Mohammad Sal |
Impact of organic anion transporting polypeptide, P-glycoprotein, and breast cancer resistance protein transporters on observed tamoxifen and endoxifen concentration and adverse effects. Pharmacogenetics and genomics 2022 11 33 (1): 10-18. Keller Denise N, Medwid Samantha J, Ross Cameron D, Wigle Theodore J, Kim Richard |
The frequencies of CYP2D6 alleles and their impact on clinical outcomes of adjuvant tamoxifen therapy in Syrian breast cancer patients. BMC cancer 2022 Oct 22 (1): 1067. Ismail Al-Khalil Wouroud, Al-Salhi Lana, Rijjal Sara, Aljamali Majd, Youssef Lama |
Association between genetic polymorphisms in cytochrome P450 enzymes and survivals in women with breast cancer receiving adjuvant endocrine therapy: a systematic review and meta-analysis. Expert reviews in molecular medicine 2022 1 24 e1. Chan Carmen Wing Han, Li Caixia, Xiao Eleven Jinnan, Li Minjie, Phiri Patrick Gladson McLeywick, Yan Tingting, Chan Judy Yuet |
Flexible Etherified and Esterified Triphenylethylene Derivatives and Their Evaluation on ER-positive and Triple-Negative Breast Cancer Cell Lines. ChemMedChem 2022 Jan e202100720. Hassan Aya S, Wober Jannette, Vollmer Günter, Abadi Ashraf H, Ahmed Nermin |
Toremifene, an Alternative Adjuvant Endocrine Therapy, Is Better than Tamoxifen in Breast Cancer Patients with CYP2D6*10 Mutant Genotypes. Cancer research and treatment 2023 8 . Xin Li, Zehao Li, Lin Li, Tong Liu, Cheng Qian, Yanlv Ren, Zhigao Li, Kejin Chen, Dongchen Ji, Ming Zhang, Jinsong Wa |
Predictive modeling of adverse drug reactions to tamoxifen therapy for breast cancer on base of pharmacogenomic testing. Drug metabolism and personalized therapy 2023 7 . Ekaterina Olegovna Golubenko, Marina Ivanovna Savelyeva, Zhannet Alimovna Sozaeva, Vera Vyacheslavovna Korennaya, Irina Vladimirovna Poddubnaya, Timur Tejmurazovich Valiev, Svetlana Nikolaevna Kondratenko, Mikhail Vitalyevich Ily |
Pharmacogenetics and pharmacokinetics of tamoxifen in a Zimbabwean breast cancer cohort. British journal of clinical pharmacology 2023 6 . Bianza Tinotenda Mbavha, Roslyn Stella Thelingwani, Zedias Chikwambi, Anna Mary Nyakabau, Collen Masimirembwa, |
Profiling of pharmacogenomic variants in CYP2D6 and DPYD in indigenous Arab breast cancer patients. Pharmacogenomics 2023 5 . Abdullah Alsulaiman, Hoyin Chu, Mohammed Al-Jumaan, Mohammed Alyahya, Yousef Al Marzooq, Fatmah Almulhim, Chittibabu Vatte, Areej Alnimer, Afnan Almuhanna, Amein Al-Ali, Saud H AlDubay |
Early increase in tamoxifen dose in CYP2D6 poor metaboliser breast cancer patients and survival: A propensity score matching analysis. Breast (Edinburgh, Scotland) 2023 4 69 342-348. Blancas Isabel, Linares-Rodríguez Marina, Martínez de Dueñas Eduardo, Herrero-Vicent Carmen, Molero-Mir María D, Garrido José M, Rodríguez-Serrano Fernan |
Tamoxifen pharmacokinetics and pharmacodynamics in older patients with non-metastatic breast cancer. Breast cancer research and treatment 2023 4 . Souwer E T D, Sanchez-Spitman A, Moes D J A R, Gelderblom H, Swen J J, Portielje J E A, Guchelaar H J, van Gelder |
Toward model-informed precision dosing for tamoxifen: A population-pharmacokinetic model with a continuous CYP2D6 activity scale. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2023 2 160 114369. Agema Bram C, Buijs Sanne M, Sassen Sebastiaan D T, Mürdter Thomas E, Schwab Mathias, Koch Birgit C P, Jager Agnes, van Schaik Ron H N, Mathijssen Ron H J, Koolen Stijn L |
Pharmacokinetics of Tamoxifen and Its Major Metabolites and the Effect of the African Ancestry Specific CYP2D6*17 Variant on the Formation of the Active Metabolite, Endoxifen. Journal of personalized medicine 2023 2 13 (2): . Kanji Comfort Ropafadzo, Nyabadza Georginah, Nhachi Charles, Masimirembwa Coll |
Effect of genetic polymorphisms on the pharmacokinetics of gefitinib in healthy Chinese volunteers. Xenobiotica; the fate of foreign compounds in biological systems 2023 12 1-28. Ying-Rong Chen, Xiang Yu, Li-Min Xu, Jue Mei, Meng-Li Tian, Min Xu, Qiu-Yue Jin, Li-Bing Ye, Shui-Xin Ya |
Evaluation of the effect of CYP2D6*3, *4,*10, and *17 polymorphisms on the pharmacokinetic of tamoxifen and its metabolites in patients with hormone-positive breast cancer. Journal of pharmaceutical and biomedical analysis 2023 11 238 115839. Fatemeh Saghafi, Ebrahim Salehifar, Pouneh Ebrahimi, Mohammad Reza Shiran, Ehsan Zaboli, Seyed Mojtaba Sohrevardi, Tannaz Jamialahmadi, Adeleh Sahebnasagh, Amirhossein Sahebk |
CYP2D6 genotyping and the clinical impact on outcomes in breast cancer tamoxifen-treated patients. Personalized medicine 2023 11 . Gabriel Ramírez, Marcelo Vital, Carolina Vergara, Florencia Carusso, Florencia Neffa, Adriana Della Valle, Patricia Esper |
Cross-Ancestry Genome-Wide Association Study Defines the Extended CYP2D6 Locus as the Principal Genetic Determinant of Endoxifen Plasma Concentrations.
Clinical pharmacology and therapeutics 2023 1 113 (3): 712-723. Khor Chiea Chuen, Winter Stefan, Sutiman Natalia, Mürdter Thomas E, Chen Sylvia, Lim Joanne Siok Liu, Li Zheng, Li Jingmei, Sim Kar Seng, Ganchev Boian, Eccles Diana, Eccles Bryony, Tapper William, Zgheib Nathalie K, Tfayli Arafat, Ng Raymond Chee Hui, Yap Yoon Sim, Lim Elaine, Wong Mabel, Wong Nan Soon, Ang Peter Cher Siang, Dent Rebecca, Tremmel Roman, Klein Kathrin, Schaeffeler Elke, Zhou Yitian, Lauschke Volker M, Eichelbaum Michel, Schwab Matthias, Brauch Hiltrud B, Chowbay Balram, Schroth Wern |
Distribution of CYP2D6 and CYP2C19 gene polymorphisms in Han and Uygur populations with breast cancer in Xinjiang, China. Open life sciences 2024 4 19 (1): 20220728. Muzhapaer Abudukeremu, Aisikaer Ayoufu, Adila Tuerhong, Xuelaiti Paizula, Jiang-Hua |
- Page last reviewed:Feb 1, 2024
- Page last updated:Jun 11, 2024
- Content source: